Results 1 to 10 of about 15,348 (191)
PHYSICOCHEMICAL CHARACTERIZATION OF MOUSE MYELOMA PROTEINS: DEMONSTRATION OF HETEROGENEITY FOR EACH MYELOMA GLOBULIN [PDF]
The Journal of Experimental Medicine, 1961 Physicochemical characterization of mouse myeloma proteins revealed the individuality of each myeloma protein. When the myeloma proteins are considered collectively a wide range of individual properties were represented, including electrophoretic mobilities varying from the gamma to alpha region, hexose contents from 1 to 4 per cent, and ...
John L. Fahey
openalex +5 more sources
Myeloma protein kinetics following chemotherapy [PDF]
Blood, 1982 The effects of chemotherapy were evaluated in 43 multiple myeloma patients with high monoclonal globulin levels in both serum and urine. In responding patients, Bence Jones protein excretion declined more rapidly and markedly than the serum myeloma protein.
P McLaughlin, Raymond Alexanian
openalex +5 more sources
Cell-Bound Myeloma Proteins on the Surface of Myeloma Cells: Potential Targets for the Immune System [PDF]
Proceedings of the National Academy of Sciences, 1972 Rosette formation with 2,4,6-trinitrophenylated (Tnp)-sheep erythrocytes was used to demonstrate cell-bound myeloma proteins on cells from each of the eleven mouse plasmacytomas tested. Tnp-erythrocytes were bound directly by cells from two tumors (MOPC-315 and MOPC-460) that formed myeloma proteins with antihapten combining sites; rosette formation ...
Kristian Hannestad +2 more
openalex +5 more sources
Pharmaceuticals, 2023 Exposure of many cancer cells, including multiple myeloma cells, to cytotoxic concentrations of natural products celastrol and withaferin A or synthetic compounds of the IHSF series resulted in denaturation of a luciferase reporter protein.
Nuria Vilaboa +6 more
doaj +1 more source
HemaSphere, 2023 Despite the recent introduction of next-generation immunotherapeutic agents, multiple myeloma (MM) remains incurable. New strategies targeting MM-specific antigens may result in a more effective therapy by preventing antigen escape, clonal evolution, and
Margaux Lejeune +12 more
doaj +1 more source
Cells, 2021 BH3-mimetics targeting anti-apoptotic proteins such as MCL-1 (S63845) or BCL-2 (venetoclax) are currently being evaluated as effective therapies for the treatment of multiple myeloma (MM).
Esperanza M. Algarín +14 more
doaj +1 more source
Scientific Reports, 2022 DNA cytosine deaminase APOBEC3B (A3B) is an endogenous source of mutations in many human cancers, including multiple myeloma. A3B proteins form catalytically inactive high molecular mass (HMM) complexes in nuclei, however, the regulatory mechanisms of ...
Yasuhiro Kazuma +14 more
doaj +1 more source
Myeloma Proteins, Bence Jones Proteins and Normal Immunoglobulins in Multiple Myeloma [PDF]
Blood, 1967 Abstract The relationship between the anomalous and normal immunoglobulins was studied through measurement of myeloma protein (MP), Bence Jones protein (BJP), and the normal γG, γA, γM and γD-globulin levels in a large group of patients with multiple myeloma. These determinations were made prior to and after initiation of three different
Vincent Caggiano +3 more
openaire +3 more sources
Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients
Frontiers in Immunology, 2020 Previous studies showed that monoclonal immunoglobulins G (IgGs) of “monoclonal gammopathy of undetermined significance” (MGUS) and myeloma were hyposialylated, thus presumably pro-inflammatory, and for about half of patients, the target of the ...
Adrien Bosseboeuf +19 more
doaj +1 more source
Haematologica, 2018 Protein analysis in bone marrow samples from patients with multiple myeloma has been limited by the low concentration of proteins obtained after CD138+ cell selection.
Irena Misiewicz-Krzeminska +10 more
doaj +1 more source